Covered recipient · General Payments record
JOHN W MCCONNELL
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$140,087.04
155 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $77,155.00 | 19 |
| Consulting Fee | $42,031.25 | 10 |
| Travel and Lodging | $15,120.19 | 41 |
| Food and Beverage | $5,758.90 | 84 |
| Education | $21.70 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $99,261.16 | 96 |
| Merck Sharp & Dohme LLC | $20,660.28 | 38 |
| Bayer Healthcare Pharmaceuticals Inc. | $16,600.43 | 11 |
| Johnson & Johnson Health Care Systems Inc. | $2,700.00 | 2 |
| United Therapeutics Corporation | $242.73 | 2 |
| Vero Biotech Inc. | $218.53 | 2 |
| Abbott Laboratories | $139.16 | 1 |
| AstraZeneca Pharmaceuticals LP | $123.24 | 1 |
| GlaxoSmithKline, LLC. | $108.42 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $33.09 | 1 |
Page 4 of 4; records 151–155 of 155 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN W MCCONNELL
NPI 1902831761 · CMS profile ID 40381
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
LOUISVILLE, KY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–155 of 155 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1902831761?year=2024&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN W MCCONNELL, NPI 1902831761, CMS profile ID 40381. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–155 of 155 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902831761?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JOHN W MCCONNELL, NPI 1902831761, CMS profile ID 40381. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–155 of 155 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902831761?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JOHN W MCCONNELL, NPI 1902831761, CMS profile ID 40381, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–155 of 155 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1902831761?year=2024&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
155 matching records · $140,087.04 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–155 of 155.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $860.83 | 03/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141880185 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $121.84 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086203241 | CMS |
| Actelion Pharmaceuticals US, Inc. | $109.60 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078888745 | CMS |
| United Therapeutics Corporation | $111.31 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149450183 | CMS |
| Actelion Pharmaceuticals US, Inc. | $25.28 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078888865 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $628,069.55 | 56 |
| PY2024 | Principal investigator | $890,582.96 | 49 |
| PY2023 | Recipient | $1,159.37 | 1 |
| PY2023 | Principal investigator | $285,471.40 | 29 |
| PY2022 | Principal investigator | $252,421.74 | 11 |
| PY2021 | Principal investigator | $167,628.46 | 24 |
| PY2020 | Principal investigator | $204,781.37 | 27 |
| PY2019 | Principal investigator | $243,121.25 | 36 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
56 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $116,744.44 | 12/31/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organization WHO Functional Class FC III o | No dispute reported | 06/30/2026 | 1232917471 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $19,869.90 | 12/31/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038 | No dispute reported | 06/30/2026 | 1232934250 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,592.43 | 12/31/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038 | No dispute reported | 06/30/2026 | 1232934252 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $28,028.29 | 12/31/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF | No dispute reported | 06/30/2026 | 1232938096 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $12,032.58 | 12/31/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF | No dispute reported | 06/30/2026 | 1232938098 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $180,119.46 | 12/31/2025 | Covered Recipient Teaching Hospital Norton Hospitals Inc | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F | No dispute reported | 06/30/2026 | 1232938440 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $11,829.50 | 12/31/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on | No dispute reported | 06/30/2026 | 1232938902 |
| Principal investigator 1 | United Therapeutics Corporation | $1,592.96 | 12/24/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387051 |
| Principal investigator 1 | United Therapeutics Corporation | $1,617.28 | 12/24/2025 | Non-covered Recipient Entity Norton Healthcare Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387069 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $23,201.00 | 12/17/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF | No dispute reported | 06/30/2026 | 1232938768 |
| Principal investigator 1 | United Therapeutics Corporation | $300.00 | 12/10/2025 | Non-covered Recipient Entity Norton Healthcare Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387061 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,444.00 | 12/01/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395823 |
| Principal investigator 1 | United Therapeutics Corporation | $1,425.28 | 11/26/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387049 |
| Principal investigator 1 | United Therapeutics Corporation | $1,447.04 | 11/26/2025 | Non-covered Recipient Entity Norton Healthcare Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387067 |
| Principal investigator 1 | United Therapeutics Corporation | $4,695.04 | 11/12/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387059 |
| Principal investigator 1 | United Therapeutics Corporation | $1,000.00 | 11/12/2025 | Non-covered Recipient Entity Norton Healthcare Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387063 |
| Principal investigator 1 | United Therapeutics Corporation | $4,766.72 | 11/12/2025 | Non-covered Recipient Entity Norton Healthcare Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387075 |
| Principal investigator 1 | United Therapeutics Corporation | $7,766.54 | 11/12/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | No dispute reported | 06/30/2026 | 1242387085 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $14,446.68 | 11/03/2025 | Non-covered Recipient Entity NORTON INFECTIOUS DISEASES SPECIALISTS | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for th | No dispute reported | 06/30/2026 | 1190308860 |
| Principal investigator 1 | Janssen Research & Development, LLC | $181.00 | 10/30/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395859 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,344.00 | 09/04/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395801 |
| Principal investigator 1 | Janssen Research & Development, LLC | $124.00 | 08/29/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395841 |
| Principal investigator 1 | United Therapeutics Corporation | $156.94 | 08/13/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | No dispute reported | 06/30/2026 | 1242387081 |
| Principal investigator 1 | United Therapeutics Corporation | $8,650.00 | 08/13/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | No dispute reported | 06/30/2026 | 1242387087 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,532.72 | 07/30/2025 | Covered Recipient Teaching Hospital Norton Hospitals Inc | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH | No dispute reported | 06/30/2026 | 1232938818 |
| Principal investigator 1 | PFIZER INC. | $17,479.75 | 07/25/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A PHASE 1 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING DOSES OF PF07868489 IN HEALTHY ADULT PARTICIPANTS AND REPEAT DOSES IN PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION | No dispute reported | 06/30/2026 | 1228772250 |
| Principal investigator 1 | United Therapeutics Corporation | $3,236.40 | 07/23/2025 | Non-covered Recipient Entity Norton Healthcare Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387073 |
| Principal investigator 1 | United Therapeutics Corporation | $3,018.24 | 07/08/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387057 |
| Principal investigator 1 | United Therapeutics Corporation | $3,064.32 | 07/08/2025 | Non-covered Recipient Entity Norton Healthcare Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387071 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $16,355.00 | 07/07/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on | No dispute reported | 06/30/2026 | 1232938900 |
| Principal investigator 1 | Janssen Research & Development, LLC | $130.00 | 07/03/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395806 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,344.00 | 06/26/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395853 |
| Principal investigator 1 | United Therapeutics Corporation | $1,908.67 | 06/25/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387053 |
| Principal investigator 1 | United Therapeutics Corporation | $1,257.52 | 06/25/2025 | Non-covered Recipient Entity Norton Healthcare Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387065 |
| Principal investigator 1 | United Therapeutics Corporation | $4,282.00 | 06/20/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | No dispute reported | 06/30/2026 | 1242387083 |
| Principal investigator 1 | United Therapeutics Corporation | $2,515.20 | 06/11/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387055 |
| Principal investigator 1 | United Therapeutics Corporation | $12,655.00 | 06/11/2025 | Non-covered Recipient Entity Norton Healthcare Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387077 |
| Principal investigator 1 | United Therapeutics Corporation | $25,110.40 | 06/11/2025 | Non-covered Recipient Entity Norton Healthcare Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387079 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,456.87 | 06/06/2025 | Covered Recipient Teaching Hospital Norton Hospitals Inc | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F | No dispute reported | 06/30/2026 | 1232938442 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,444.00 | 05/26/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395836 |
| Principal investigator 1 | Janssen Research & Development, LLC | $248.00 | 05/19/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395829 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,614.00 | 05/14/2025 | Covered Recipient Teaching Hospital Norton Hospitals Inc | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1236000462 |
| Principal investigator 1 | United Therapeutics Corporation | $1,162.63 | 05/07/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387045 |
| Principal investigator 1 | United Therapeutics Corporation | $1,425.28 | 05/07/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387047 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $225.00 | 04/28/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | BAY 632521, RiOciguAt UseRs Registry The ROAR registry | No dispute reported | 06/30/2026 | 1225419745 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $12,984.72 | 04/28/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | BAY 632521, RiOciguAt UseRs Registry The ROAR registry | No dispute reported | 06/30/2026 | 1225419791 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $8,889.27 | 04/28/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | BAY 632521, RiOciguAt UseRs Registry The ROAR registry | No dispute reported | 06/30/2026 | 1225419821 |
| Principal investigator 1 | Janssen Research & Development, LLC | $181.00 | 04/28/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395846 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,140.67 | 04/10/2025 | Non-covered Recipient Entity Norton Pulmonary Specialists | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1235995141 |
| Principal investigator 1 | United Therapeutics Corporation | $838.40 | 04/09/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387043 |
| Principal investigator 1 | United Therapeutics Corporation | $1,676.80 | 02/26/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387037 |
| Principal investigator 1 | United Therapeutics Corporation | $1,908.67 | 02/12/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387039 |
| Principal investigator 1 | United Therapeutics Corporation | $2,766.72 | 02/12/2025 | Non-covered Recipient Entity Norton Healthcare Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242387041 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,629.00 | 02/10/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395819 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $36,671.22 | 01/30/2025 | Covered Recipient Teaching Hospital Norton Hospitals Inc | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1236000460 |
| Principal investigator 1 | Janssen Research & Development, LLC | $543.00 | 01/27/2025 | Non-covered Recipient Entity COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. | No dispute reported | 06/30/2026 | 1175395813 |